Advertisement

World Journal of Urology

, Volume 37, Issue 1, pp 61–83 | Cite as

SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer

  • Jeffrey J. Leow
  • Jens Bedke
  • Karim Chamie
  • Justin W. Collins
  • Siamak Daneshmand
  • Petros Grivas
  • Axel Heidenreich
  • Edward M. Messing
  • Trevor J. Royce
  • Alexander I. Sankin
  • Mark P. Schoenberg
  • William U. Shipley
  • Arnauld Villers
  • Jason A. EfstathiouEmail author
  • Joaquim BellmuntEmail author
  • Arnulf StenzlEmail author
Topic Paper

Abstract

Purpose

To provide a comprehensive overview and update of the Joint Société Internationale d’Urologie–International Consultation on Urological Diseases (SIU–ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC).

Methods

Contemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine.

Results

Radical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligible ≥ cT2N0 patients. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3–4 and/or pN+ disease without prior NA chemotherapy. Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Immunotherapy is still experimental and is given either alone or in combination with chemotherapy and/or radiation.

Conclusion

A multi-disciplinary approach is paramount to achieving optimal outcomes for MIBC patients, irrespective of their age, performance and nutritional status, fitness/frailty, renal and other organ function, or disease severity.

Keywords

Muscle-invasive bladder cancer Urothelial carcinoma of bladder Radical cystectomy Transurethral resection of bladder tumor Neoadjuvant chemotherapy Adjuvant chemotherapy Chemoradiation Trimodal Bladder-sparing Variant histology Enhanced recovery after surgery 

Notes

Author contributions

JJL: project development, data analysis, manuscript writing and editing; JB: data analysis and manuscript editing; KC: data analysis and manuscript editing; JWC: data analysis and manuscript editing; SD: data analysis and manuscript editing; PG: data analysis and manuscript editing; AH: data analysis and manuscript editing; EMM: data analysis and manuscript editing; TJR: data analysis and manuscript editing; AIS: data analysis and manuscript editing; MPS: data analysis and manuscript editing; WUS: data analysis and manuscript editing; AV: data analysis and manuscript editing; JAE: project development, data analysis, manuscript writing and editing; JB: project development, data analysis, manuscript writing and editing; AS: project development, data analysis, manuscript writing and editing.

Funding

No funding was obtained for this study.

Compliance with ethical standards

Conflict of interest

The authors declare no directly related conflicts of interest.

Ethical approval

The study was conducted according to the Declaration of Helsinki.

References

  1. 1.
    Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder C (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63(1):45–57.  https://doi.org/10.1016/j.eururo.2012.08.009 Google Scholar
  2. 2.
    Philips B, Ball C, Sackett D et al (2009) Oxford centre for evidence-based medicine—levels of evidence. https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
  3. 3.
    Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3):666–675Google Scholar
  4. 4.
    Bostrom PJ, Mirtti T, Kossi J, Laato M, Nurmi M (2009) Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre. Scand J Urol Nephrol 43(5):357–364.  https://doi.org/10.3109/00365590902939387 Google Scholar
  5. 5.
    Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L, European Organization for R, Treatment of Cancer Genitourinary Tract Cancer Cooperative G (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: european Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19(10):2638–2646Google Scholar
  6. 6.
    Herr HW, Bajorin DF, Scher HI (1998) Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 16(4):1298–1301Google Scholar
  7. 7.
    Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, Mills RD, Montie JD, Sagalowsky AI, Stein JP, Stenzl A, Studer UE, Volkmer BG (2007) Urinary diversion. Urology 69(1 Suppl):17–49Google Scholar
  8. 8.
    Fleischmann A, Thalmann GN, Markwalder R, Studer UE (2005) Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 23(10):2358–2365.  https://doi.org/10.1200/JCO.2005.03.084 Google Scholar
  9. 9.
    Stenzl A, Colleselli K, Poisel S, Feichtinger H, Pontasch H, Bartsch G (1995) Rationale and technique of nerve sparing radical cystectomy before an orthotopic neobladder procedure in women. J Urol 154(6):2044–2049Google Scholar
  10. 10.
    Wilson TG, Guru K, Rosen RC, Wiklund P, Annerstedt M, Bochner BH, Chan KG, Montorsi F, Mottrie A, Murphy D, Novara G, Peabody JO, Palou Redorta J, Skinner EC, Thalmann G, Stenzl A, Yuh B, Catto J, Pasadena Consensus P (2015) Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. Eur Urol 67(3):363–375.  https://doi.org/10.1016/j.eururo.2014.12.009 Google Scholar
  11. 11.
    Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866.  https://doi.org/10.1056/NEJMoa022148 Google Scholar
  12. 12.
    Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED (2004) Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 22(14):2781–2789Google Scholar
  13. 13.
    Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, European Association of U (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59(6):1009–1018.  https://doi.org/10.1016/j.eururo.2011.03.023 Google Scholar
  14. 14.
    Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE (2001) Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 166(1):19–23Google Scholar
  15. 15.
    Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF (2002) Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 167(3):1295–1298Google Scholar
  16. 16.
    Leissner J, Allhoff EP, Hohenfellner R, Wolf HK (2003) Ranking of pelvic lymphadenectomy in therapy and prognosis of carcinoma of the bladder. Aktuelle Urol 34(6):392–397.  https://doi.org/10.1055/s-2003-43173 Google Scholar
  17. 17.
    Stein JP, Cai J, Groshen S, Skinner DG (2003) Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 170(1):35–41Google Scholar
  18. 18.
    Leissner J, Hohenfellner R, Thuroff JW, Wolf HK (2000) Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 85(7):817–823Google Scholar
  19. 19.
    Bochner BH, Herr HW, Reuter VE (2001) Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166(6):2295–2296Google Scholar
  20. 20.
    Hollenbeck BK, Ye Z, Wong SL, Montie JE, Birkmeyer JD (2008) Hospital lymph node counts and survival after radical cystectomy. Cancer 112(4):806–812.  https://doi.org/10.1002/cncr.23234 Google Scholar
  21. 21.
    Konety BR, Joslyn SA, O’Donnell MA (2003) Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 169(3):946–950Google Scholar
  22. 22.
    Gschwend JE, Heck MM, Lehmann J, Rubben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kalble T, Stockle M, Schnoller T, Stenzl A, Muller M, Truss M, Roth S, Liehr UB, Leissner J, Bregenzer T, Retz M (2018) Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol.  https://doi.org/10.1016/j.eururo.2018.09.047 Google Scholar
  23. 23.
    Novara G, Catto JW, Wilson T, Annerstedt M, Chan K, Murphy DG, Motttrie A, Peabody JO, Skinner EC, Wiklund PN, Guru KA, Yuh B (2015) Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol 67(3):376–401.  https://doi.org/10.1016/j.eururo.2014.12.007 Google Scholar
  24. 24.
    Tang K, Xia D, Li H, Guan W, Guo X, Hu Z, Ma X, Zhang X, Xu H, Ye Z (2014) Robotic vs. open radical cystectomy in bladder cancer: A systematic review and meta-analysis. Eur J Surg Oncol 40(11):1399–1411.  https://doi.org/10.1016/j.ejso.2014.03.008 Google Scholar
  25. 25.
    Tyritzis SI, Hosseini A, Collins J, Nyberg T, Jonsson MN, Laurin O, Khazaeli D, Adding C, Schumacher M, Wiklund NP (2013) Oncologic, functional, and complications outcomes of robot-assisted radical cystectomy with totally intracorporeal neobladder diversion. Eur Urol 64(5):734–741.  https://doi.org/10.1016/j.eururo.2013.05.050 Google Scholar
  26. 26.
    Collins JW, Wiklund NP (2014) Totally intracorporeal robot-assisted radical cystectomy: optimizing total outcomes. BJU Int 114(3):326–333.  https://doi.org/10.1111/bju.12558 Google Scholar
  27. 27.
    Adding C, Collins JW, Laurin O, Hosseini A, Wiklund NP (2015) Enhanced recovery protocols (ERP) in robotic cystectomy surgery. Review of current status and trends. Curr Urol Rep 16(5):32.  https://doi.org/10.1007/s11934-015-0497-7 Google Scholar
  28. 28.
    Leow JJ, Reese SW, Jiang W, Lipsitz SR, Bellmunt J, Trinh QD, Chung BI, Kibel AS, Chang SL (2014) Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol 66(3):569–576.  https://doi.org/10.1016/j.eururo.2014.01.029 Google Scholar
  29. 29.
    Raza SJ, Al-Daghmin A, Zhuo S, Mehboob Z, Wang K, Wilding G, Kauffman E, Guru KA (2014) Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience. Eur Urol 66(5):920–928.  https://doi.org/10.1016/j.eururo.2014.03.015 Google Scholar
  30. 30.
    Raza SJ, Wilson T, Peabody JO, Wiklund P, Scherr DS, Al-Daghmin A, Dibaj S, Khan MS, Dasgupta P, Mottrie A, Menon M, Yuh B, Richstone L, Saar M, Stoeckle M, Hosseini A, Kaouk J, Mohler JL, Rha KH, Wilding G, Guru KA (2015) Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 68(4):721–728.  https://doi.org/10.1016/j.eururo.2015.04.021 Google Scholar
  31. 31.
    Davis JW, Castle EP, Pruthi RS, Ornstein DK, Guru KA (2010) Robot-assisted radical cystectomy: an expert panel review of the current status and future direction. Urol Oncol 28(5):480–486.  https://doi.org/10.1016/j.urolonc.2009.11.014 Google Scholar
  32. 32.
    Dotan ZA, Kavanagh K, Yossepowitch O, Kaag M, Olgac S, Donat M, Herr HW (2007) Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol 178(6):2308–2312.  https://doi.org/10.1016/j.juro.2007.08.023 (discussion 2313) Google Scholar
  33. 33.
    Hellenthal NJ, Hussain A, Andrews PE, Carpentier P, Castle E, Dasgupta P, Kaouk J, Khan S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Palou J, Peabody J, Pruthi R, Richstone L, Schanne F, Stricker H, Thomas R, Wiklund P, Wilding G, Guru KA (2010) Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol 184(1):87–91.  https://doi.org/10.1016/j.juro.2010.03.037 Google Scholar
  34. 34.
    Collins JW, Tyritzis S, Nyberg T, Schumacher MC, Laurin O, Adding C, Jonsson M, Khazaeli D, Steineck G, Wiklund P, Hosseini A (2014) Robot-assisted radical cystectomy (RARC) with intracorporeal neobladder—what is the effect of the learning curve on outcomes? BJU Int 113(1):100–107.  https://doi.org/10.1111/bju.12347 Google Scholar
  35. 35.
    Collins JW, Adding C, Hosseini A, Nyberg T, Pini G, Dey L, Wiklund PN (2016) Introducing an enhanced recovery programme to an established totally intracorporeal robot-assisted radical cystectomy service. Scand J Urol 50(1):39–46.  https://doi.org/10.3109/21681805.2015.1076514 Google Scholar
  36. 36.
    Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM (2018) Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 391(10139):2525–2536.  https://doi.org/10.1016/S0140-6736(18)30996-6 Google Scholar
  37. 37.
    Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS (2010) Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 57(2):196–201.  https://doi.org/10.1016/j.eururo.2009.10.024 Google Scholar
  38. 38.
    Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, Munsell MF, Kamat AM (2011) Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol 185(1):79–83.  https://doi.org/10.1016/j.juro.2010.09.031 Google Scholar
  39. 39.
    Yuh B, Wilson T, Bochner B, Chan K, Palou J, Stenzl A, Montorsi F, Thalmann G, Guru K, Catto JW, Wiklund PN, Novara G (2015) Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. Eur Urol 67(3):402–422.  https://doi.org/10.1016/j.eururo.2014.12.008 Google Scholar
  40. 40.
    Fonseka T, Ahmed K, Froghi S, Khan SA, Dasgupta P, Shamim Khan M (2015) Comparing robotic, laparoscopic and open cystectomy: a systematic review and meta-analysis. Arch Ital Urol Androl 87(1):41–48.  https://doi.org/10.4081/aiua.2015.1.41 Google Scholar
  41. 41.
    Marshall SJ, Hayn MH, Stegemann AP, Agarwal PK, Badani KK, Balbay MD, Dasgupta P, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Palou Redorta J, Rha KH, Richstone L, Schanne F, Scherr DS, Siemer S, Stockle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Guru KA (2013) Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). BJU Int 111(7):1075–1080.  https://doi.org/10.1111/j.1464-410X.2012.11583.x Google Scholar
  42. 42.
    Khan MS, Gan C, Ahmed K, Ismail AF, Watkins J, Summers JA, Peacock JL, Rimington P, Dasgupta P (2016) A single-centre early phase randomised controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy (CORAL). Eur Urol 69(4):613–621.  https://doi.org/10.1016/j.eururo.2015.07.038 Google Scholar
  43. 43.
    Lenfant L, Verhoest G, Campi R, Parra J, Graffeille V, Masson-Lecomte A, Vordos D, de La Taille A, Roumiguie M, Lesourd M, Taksin L, Misrai V, Grande P, Vaessen C, Ploussard G, Granger B, Roupret M (2018) Perioperative outcomes and complications of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy for bladder cancer: a real-life, multi-institutional french study. World J Urol.  https://doi.org/10.1007/s00345-018-2313-8 Google Scholar
  44. 44.
    Catto JWF, Khetrapal P, Ambler G, Sarpong R, Khan MS, Tan M, Feber A, Dixon S, Goodwin L, Williams NR, McGrath J, Rowe E, Koupparis A, Brew-Graves C, Kelly JD (2018) Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. BMJ Open 8(8):e020500.  https://doi.org/10.1136/bmjopen-2017-020500 Google Scholar
  45. 45.
    Lauridsen SV, Tonnesen H, Jensen BT, Neuner B, Thind P, Thomsen T (2017) Complications and health-related quality of life after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis of four RCTs. Syst Rev 6(1):150.  https://doi.org/10.1186/s13643-017-0547-y Google Scholar
  46. 46.
    Kehlet H (1997) Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth 78(5):606–617Google Scholar
  47. 47.
    Gandaglia G, Varda B, Sood A, Pucheril D, Konijeti R, Sammon JD, Sukumar S, Menon M, Sun M, Chang SL, Montorsi F, Kibel AS, Trinh QD (2014) Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Can Urol Assoc J 8(9–10):E681–E687.  https://doi.org/10.5489/cuaj.2069 Google Scholar
  48. 48.
    Maffezzini M, Campodonico F, Capponi G, Manuputty E, Gerbi G (2012) Fast-track surgery and technical nuances to reduce complications after radical cystectomy and intestinal urinary diversion with the modified Indiana pouch. Surg Oncol 21(3):191–195.  https://doi.org/10.1016/j.suronc.2012.02.001 Google Scholar
  49. 49.
    Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC (2003) A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 43(3):246–257Google Scholar
  50. 50.
    Arumainayagam N, McGrath J, Jefferson KP, Gillatt DA (2008) Introduction of an enhanced recovery protocol for radical cystectomy. BJU Int 101(6):698–701.  https://doi.org/10.1111/j.1464-410X.2007.07319.x Google Scholar
  51. 51.
    Collins JW, Patel H, Adding C, Annerstedt M, Dasgupta P, Khan SM, Artibani W, Gaston R, Piechaud T, Catto JW, Koupparis A, Rowe E, Perry M, Issa R, McGrath J, Kelly J, Schumacher M, Wijburg C, Canda AE, Balbay MD, Decaestecker K, Schwentner C, Stenzl A, Edeling S, Pokupic S, Stockle M, Siemer S, Sanchez-Salas R, Cathelineau X, Weston R, Johnson M, D’Hondt F, Mottrie A, Hosseini A, Wiklund PN (2016) Enhanced recovery after robot-assisted radical cystectomy: EAU robotic urology section scientific working group consensus view. Eur Urol 70(4):649–660.  https://doi.org/10.1016/j.eururo.2016.05.020 Google Scholar
  52. 52.
    Novotny V, Hakenberg OW, Wiessner D, Heberling U, Litz RJ, Oehlschlaeger S, Wirth MP (2007) Perioperative complications of radical cystectomy in a contemporary series. Eur Urol 51(2):397–401.  https://doi.org/10.1016/j.eururo.2006.06.014 (discussion 401-392) Google Scholar
  53. 53.
    Lowrance WT, Rumohr JA, Chang SS, Clark PE, Smith JA Jr, Cookson MS (2008) Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol 179(4):1313–1318.  https://doi.org/10.1016/j.juro.2007.11.084 (discussion 1318) Google Scholar
  54. 54.
    Nieuwenhuijzen JA, de Vries RR, Bex A, van der Poel HG, Meinhardt W, Antonini N, Horenblas S (2008) Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol 53(4):834–842.  https://doi.org/10.1016/j.eururo.2007.09.008 (discussion 842-834) Google Scholar
  55. 55.
    Goldhaber SZ (2010) Risk factors for venous thromboembolism. J Am Coll Cardiol 56(1):1–7.  https://doi.org/10.1016/j.jacc.2010.01.057 Google Scholar
  56. 56.
    Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW, Donat SM (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55(1):164–174Google Scholar
  57. 57.
    Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA Jr (2003) Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 169(1):101–104.  https://doi.org/10.1097/01.ju.0000039521.77948.f9 Google Scholar
  58. 58.
    Faba OR, Tyson MD, Artibani W, Bochner BH, Burkhard F, Gilbert SM, Kalble T, Madersbacher S, Seiler R, Skinner EC, Thalmann G, Thuroff J, Wiklund P, Hautmann R, Palou J (2018) Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion. World J Urol.  https://doi.org/10.1007/s00345-018-2484-3 Google Scholar
  59. 59.
    Hautmann RE, de Petriconi R, Gottfried HW, Kleinschmidt K, Mattes R, Paiss T (1999) The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 161(2):422–427 (discussion 427–428) Google Scholar
  60. 60.
    Madersbacher S, Schmidt J, Eberle JM, Thoeny HC, Burkhard F, Hochreiter W, Studer UE (2003) Long-term outcome of ileal conduit diversion. J Urol 169(3):985–990.  https://doi.org/10.1097/01.ju.0000051462.45388.14 Google Scholar
  61. 61.
    Kouba E, Sands M, Lentz A, Wallen E, Pruthi RS (2007) A comparison of the Bricker versus Wallace ureteroileal anastomosis in patients undergoing urinary diversion for bladder cancer. J Urol 178(3 Pt 1):945–948.  https://doi.org/10.1016/j.juro.2007.05.030 (discussion 948-949) Google Scholar
  62. 62.
    Pagano S, Ruggeri P, Rovellini P, Bottanelli A (2005) The anterior ileal conduit: results of 100 consecutive cases. J Urol 174(3):959–962.  https://doi.org/10.1097/01.ju.0000170238.24275.5c (discussion 962) Google Scholar
  63. 63.
    Bazargani ST, Djaladat H, Ahmadi H, Miranda G, Cai J, Schuckman AK, Daneshmand S (2017) Gastrointestinal complications following radical cystectomy using enhanced recovery protocol. Eur Urol Focus.  https://doi.org/10.1016/j.euf.2017.04.003 Google Scholar
  64. 64.
    Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, Smith JA Jr, Cookson MS (2010) Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol 184(4):1296–1300.  https://doi.org/10.1016/j.juro.2010.06.007 Google Scholar
  65. 65.
    Pruthi RS, Nielsen M, Smith A, Nix J, Schultz H, Wallen EM (2010) Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg 210(1):93–99.  https://doi.org/10.1016/j.jamcollsurg.2009.09.026 Google Scholar
  66. 66.
    Ramirez JA, McIntosh AG, Strehlow R, Lawrence VA, Parekh DJ, Svatek RS (2013) Definition, incidence, risk factors, and prevention of paralytic ileus following radical cystectomy: a systematic review. Eur Urol 64(4):588–597.  https://doi.org/10.1016/j.eururo.2012.11.051 Google Scholar
  67. 67.
    Daneshmand S, Ahmadi H, Schuckman AK, Mitra AP, Cai J, Miranda G, Djaladat H (2014) Enhanced recovery protocol after radical cystectomy for bladder cancer. J Urol 192(1):50–55.  https://doi.org/10.1016/j.juro.2014.01.097 Google Scholar
  68. 68.
    Djaladat H, Daneshmand S (2016) Gastrointestinal complications in patients who undergo radical cystectomy with enhanced recovery protocol. Curr Urol Rep 17(7):50.  https://doi.org/10.1007/s11934-016-0607-1 Google Scholar
  69. 69.
    Raynor MC, Pruthi RS (2013) Postoperative Ileus: time for an evidence-based consensus. Eur Urol 64(4):598–599.  https://doi.org/10.1016/j.eururo.2012.12.025 Google Scholar
  70. 70.
    Bostrom PJ, Kossi J, Laato M, Nurmi M (2009) Risk factors for mortality and morbidity related to radical cystectomy. BJU Int 103(2):191–196.  https://doi.org/10.1111/j.1464-410X.2008.07889.x Google Scholar
  71. 71.
    Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, Shariat SF, McCormack M, Valiquette L, Montorsi F, Graefen M, Saad F, Karakiewicz PI (2014) Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol 40(12):1738–1745.  https://doi.org/10.1016/j.ejso.2014.10.004 Google Scholar
  72. 72.
    Liberman D, Lughezzani G, Sun M, Alasker A, Thuret R, Abdollah F, Budaus L, Widmer H, Graefen M, Montorsi F, Shariat SF, Perrotte P, Karakiewicz PI (2011) Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology 77(3):660–666.  https://doi.org/10.1016/j.urology.2010.07.537 Google Scholar
  73. 73.
    Quek ML, Stein JP, Daneshmand S, Miranda G, Thangathurai D, Roffey P, Skinner EC, Lieskovsky G, Skinner DG (2006) A critical analysis of perioperative mortality from radical cystectomy. J Urol 175(3 Pt 1):886–889.  https://doi.org/10.1016/s0022-5347(05)00421-0 (discussion 889–890) Google Scholar
  74. 74.
    Mayer EK, Bottle A, Darzi AW, Athanasiou T, Vale JA (2010) The volume-mortality relation for radical cystectomy in England: retrospective analysis of hospital episode statistics. BMJ (Clin Res Edn) 340:c1128.  https://doi.org/10.1136/bmj.c1128 Google Scholar
  75. 75.
    Porter MP, Gore JL, Wright JL (2011) Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. World J Urol 29(1):73–77.  https://doi.org/10.1007/s00345-010-0626-3 Google Scholar
  76. 76.
    Konety BR, Dhawan V, Allareddy V, Joslyn SA (2005) Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project. J Urol 173(5):1695–1700.  https://doi.org/10.1097/01.ju.0000154638.61621.03 Google Scholar
  77. 77.
    Nielsen ME, Mallin K, Weaver MA, Palis B, Stewart A, Winchester DP, Milowsky MI (2014) Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int 114(1):46–55.  https://doi.org/10.1111/bju.12566 Google Scholar
  78. 78.
    Gandaglia G, Karakiewicz PI, Trinh QD, Sun M (2014) High hospital volume reduces mortality after cystectomy. BJU Int 114(1):5–6.  https://doi.org/10.1111/bju.12780 Google Scholar
  79. 79.
    Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, Shariat SF, Arjane P, Saad F, McCormack M, Valiquette L, Peloquin F, Duclos A, Montorsi F, Graefen M, Karakiewicz PI (2009) A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol 182(1):70–77.  https://doi.org/10.1016/j.juro.2009.02.120 Google Scholar
  80. 80.
    Boorjian SA, Kim SP, Tollefson MK, Carrasco A, Cheville JC, Thompson RH, Thapa P, Frank I (2013) Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol 190(1):55–60.  https://doi.org/10.1016/j.juro.2013.01.010 Google Scholar
  81. 81.
    Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ Jr, Aghazadeh M, Smith JA Jr, Barocas DA (2011) Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol 185(1):90–96.  https://doi.org/10.1016/j.juro.2010.09.021 Google Scholar
  82. 82.
    Morgan TM, Keegan KA, Barocas DA, Ruhotina N, Phillips SE, Chang SS, Penson DF, Clark PE, Smith JA Jr, Cookson MS (2011) Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol 186(3):829–834.  https://doi.org/10.1016/j.juro.2011.04.089 Google Scholar
  83. 83.
    Persson B, Carringer M, Andren O, Andersson SO, Carlsson J, Ljungqvist O (2015) Initial experiences with the enhanced recovery after surgery (ERAS) protocol in open radical cystectomy. Scand J Urol 49(4):302–307.  https://doi.org/10.3109/21681805.2015.1004641 Google Scholar
  84. 84.
    Koupparis A, Villeda-Sandoval C, Weale N, El-Mahdy M, Gillatt D, Rowe E (2015) Robot-assisted radical cystectomy with intracorporeal urinary diversion: impact on an established enhanced recovery protocol. BJU Int 116(6):924–931.  https://doi.org/10.1111/bju.13171 Google Scholar
  85. 85.
    Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O’Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM (2014) Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol 191(6):1721–1727.  https://doi.org/10.1016/j.juro.2013.12.015 Google Scholar
  86. 86.
    Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M (2014) Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol 66(2):265–272.  https://doi.org/10.1016/j.eururo.2014.02.036 Google Scholar
  87. 87.
    Tyson MD, Chang SS (2016) Enhanced recovery pathways versus standard care after cystectomy: a meta-analysis of the effect on perioperative outcomes. Eur Urol 70(6):995–1003.  https://doi.org/10.1016/j.eururo.2016.05.031 Google Scholar
  88. 88.
    Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V (2001) Cystectomy for bladder cancer: a contemporary series. J Urol 165(4):1111–1116Google Scholar
  89. 89.
    Soria F, Moschini M, Wirth GJ, Gust KM, Klatte T, Briganti A, Gontero P, Abufaraj M, Ozsoy M, Karakiewicz PI, Shariat SF (2017) Characterization of late recurrence after radical cystectomy in a large multicenter cohort of bladder cancer patients. Urology 106:119–124.  https://doi.org/10.1016/j.urology.2017.04.049 Google Scholar
  90. 90.
    Williams SB, Huo J, Chu Y, Baillargeon JG, Daskivich T, Kuo YF, Kosarek CD, Kim SP, Orihuela E, Tyler DS, Freedland SJ, Kamat AM (2017) Cancer and all-cause mortality in bladder cancer patients undergoing radical cystectomy: development and validation of a nomogram for treatment decision-making. Urology 110:76–83.  https://doi.org/10.1016/j.urology.2017.08.024 Google Scholar
  91. 91.
    Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J (2011) Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol 29(17):2432–2438.  https://doi.org/10.1200/jco.2011.34.8433 Google Scholar
  92. 92.
    International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research, Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29(16):2171–2177.  https://doi.org/10.1200/jco.2010.32.3139 Google Scholar
  93. 93.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361(9373):1927–1934.  https://doi.org/10.1016/S0140-6736(03)13580-5 Google Scholar
  94. 94.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48(2):202–205.  https://doi.org/10.1016/j.eururo.2005.04.006 (discussion 205–206) Google Scholar
  95. 95.
    Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ (2016) Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21(6):708–715.  https://doi.org/10.1634/theoncologist.2015-0440 Google Scholar
  96. 96.
    Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N, Douglas D, Kilbey N, Protheroe A, Chester JD (2012) Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer 118(16):3920–3927.  https://doi.org/10.1002/cncr.26675 Google Scholar
  97. 97.
    Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S (2016) Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: does dose intensity matter? Eur J Cancer 54:69–74.  https://doi.org/10.1016/j.ejca.2015.11.017 Google Scholar
  98. 98.
    Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W, Collaborators (2018) Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy. J Urol 199(6):1452–1458.  https://doi.org/10.1016/j.juro.2017.12.062 Google Scholar
  99. 99.
    Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR (2014) Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 32(18):1895–1901.  https://doi.org/10.1200/JCO.2013.53.2465 Google Scholar
  100. 100.
    Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE (2014) Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 32(18):1889–1894.  https://doi.org/10.1200/JCO.2013.52.4785 Google Scholar
  101. 101.
    Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L, Group EG-UC (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50–54.  https://doi.org/10.1016/j.ejca.2005.08.032 Google Scholar
  102. 102.
    Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I (2015) Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121(15):2586–2593.  https://doi.org/10.1002/cncr.29387 Google Scholar
  103. 103.
    Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC (2013) Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol 31(8):1737–1743.  https://doi.org/10.1016/j.urolonc.2012.07.005 Google Scholar
  104. 104.
    Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjodahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhofer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall’Era M, van der Heijden MS, Black PC (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72(4):544–554.  https://doi.org/10.1016/j.eururo.2017.03.030 Google Scholar
  105. 105.
    McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO (2016) A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 69(5):855–862.  https://doi.org/10.1016/j.eururo.2015.08.034 Google Scholar
  106. 106.
    Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, Van Kessel KE, Voskuilen CS, Winters B, Erho NG, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall’Era M, van der Heijden MS, Wright JL, Black PC (2018) Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clinical cancer research.  https://doi.org/10.1158/1078-0432.ccr-18-1106 Google Scholar
  107. 107.
    Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, Massidda B, Rubagotti A, Giannarelli D, Boccardo F, Study G (2012) Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 23(3):695–700.  https://doi.org/10.1093/annonc/mdr354 Google Scholar
  108. 108.
    Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66(1):42–54.  https://doi.org/10.1016/j.eururo.2013.08.033 Google Scholar
  109. 109.
    Paz-Ares LG, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, Hevia M, de la Rosa F, Guillem V, Bellmunt J Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. In: J Clin Oncol, ASCO Annual Meeting Proceedings, Chicago, IL, 2010. p Abstr LBA4518Google Scholar
  110. 110.
    Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Theodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R, European Organisation for R, Treatment of Cancer Genito-Urinary Cancers G, Groupe d’Etude des Tumeurs U, National Cancer Research Institute Bladder Cancer Study G, National Cancer Institute of Canada Clinical Trials G, German Association of Urologic O (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16(1):76–86.  https://doi.org/10.1016/s1470-2045(14)71160-x Google Scholar
  111. 111.
    Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, Markwalder R, Senn E, Sonntag RW (1994) Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152(1):81–84Google Scholar
  112. 112.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2006) Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2:CD006018.  https://doi.org/10.1002/14651858.cd006018 Google Scholar
  113. 113.
    Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Muller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP (2010) The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16(17):4461–4467.  https://doi.org/10.1158/1078-0432.ccr-10-0457 Google Scholar
  114. 114.
    Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, Wisnivesky JP (2016) Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol 34(8):825–832.  https://doi.org/10.1200/JCO.2015.64.1076 Google Scholar
  115. 115.
    Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, Schoenberg M, Sagalowsky AI, Lotan Y, Shariat SF (2011) Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol 185(2):456–461.  https://doi.org/10.1016/j.juro.2010.09.110 Google Scholar
  116. 116.
    Seisen T, Jamzadeh A, Leow JJ, Roupret M, Cole AP, Lipsitz SR, Kibel AS, Nguyen PL, Sun M, Menon M, Bellmunt J, Choueiri TK, Trinh QD (2017) Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy. JAMA Oncol.  https://doi.org/10.1001/jamaoncol.2017.2374 Google Scholar
  117. 117.
    Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, Investigators K- (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026.  https://doi.org/10.1056/NEJMoa1613683 Google Scholar
  118. 118.
    Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84(19):1512–1517Google Scholar
  119. 119.
    Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JH, Vermeulen W (1999) Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 284(5416):958–961Google Scholar
  120. 120.
    Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, Investigators IB (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991.  https://doi.org/10.1056/NEJMoa060570 Google Scholar
  121. 121.
    Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J (2007) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18(3):522–528Google Scholar
  122. 122.
    Li Q, Damish A, Frazier ZJ, Liu D, Reznichenko E, Kamburov A, Bell A, Zhao H, Jordan EJ, Gao SP, Ma J, Abbosh PH, Bellmunt J, Plimack ER, Lazaro JB, Solit DB, Bajorin DF, Rosenberg JE, D’Andrea AD, Riaz N, Van Allen EM, Iyer G, Mouw KW (2018) ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clin Cancer Res. 1:5–10.  https://doi.org/10.1158/1078-0432.ccr-18-1001 Google Scholar
  123. 123.
    Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE (2016) Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2(8):1094–1096.  https://doi.org/10.1001/jamaoncol.2016.1056 Google Scholar
  124. 124.
    Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68(6):959–967.  https://doi.org/10.1016/j.eururo.2015.07.009 Google Scholar
  125. 125.
    Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW, Plunkett W (1995) Cytotoxicity, metabolism, and mechanisms of action of 2′,2′-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res 55(7):1517–1524Google Scholar
  126. 126.
    Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D, Stephens C (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22(23):3548–3553Google Scholar
  127. 127.
    Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226(4673):466–468Google Scholar
  128. 128.
    Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS (2001) Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98(6):1897–1903Google Scholar
  129. 129.
    Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100(5):1282–1293Google Scholar
  130. 130.
    Monzo M, Rosell R, Sanchez JJ, Lee JS, O’Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17(6):1786–1793Google Scholar
  131. 131.
    Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, Schoenberg M, Hahn N, Hoque MO, Berman D, Bivalacqua TJ, Netto G (2015) Identification and validation of protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma. PLoS ONE 10(7):e0131245.  https://doi.org/10.1371/journal.pone.0131245 Google Scholar
  132. 132.
    Henry K, Miller J, Mori M, Loening S, Fallon B (1988) Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 140(5):964–967Google Scholar
  133. 133.
    Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19(1):89–93Google Scholar
  134. 134.
    Suer E, Hamidi N, Gokce MI, Gulpinar O, Turkolmez K, Beduk Y, Baltaci S (2016) Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World J Urol 34(6):847–851.  https://doi.org/10.1007/s00345-015-1710-5 Google Scholar
  135. 135.
    Hollenbeck BK, Taub DA, Dunn RL, Wei JT (2005) Quality of care: partial cystectomy for bladder cancer—a case of inappropriate use? J Urol 174(3):1050–1054 (discussion 1054) Google Scholar
  136. 136.
    Fedeli U, Fedewa SA, Ward EM (2011) Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 185(1):72–78Google Scholar
  137. 137.
    Vashistha V, Wang H, Mazzone A, Liss MA, Svatek RS, Schleicher M, Kaushik D (2017) Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-Analysis. Int J Radiat Oncol Biol Phys 97(5):1002–1020.  https://doi.org/10.1016/j.ijrobp.2016.11.056 Google Scholar
  138. 138.
    Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR (2017) Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 35(20):2299–2305.  https://doi.org/10.1200/JCO.2016.69.2327 Google Scholar
  139. 139.
    Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA (2017) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the massachusetts general hospital experience. Eur Urol 71(6):952–960.  https://doi.org/10.1016/j.eururo.2016.12.020 Google Scholar
  140. 140.
    Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA (2018) Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol 19(12):e683–e695Google Scholar
  141. 141.
    Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu C-L, Drumm MR, Batista da Costa J, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT (2019) Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer. Eur Urol (in press)Google Scholar
  142. 142.
    Miller LS (1977) Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39(2 Suppl):973–980Google Scholar
  143. 143.
    Sell A, Jakobsen A, Nerstrom B, Sorensen BL, Steven K, Barlebo H (1991) Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 138:193–201Google Scholar
  144. 144.
    Bloom HJ, Hendry WF, Wallace DM, Skeet RG (1982) Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54(2):136–151Google Scholar
  145. 145.
    Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32(34):3801–3809.  https://doi.org/10.1200/JCO.2014.57.5548 Google Scholar
  146. 146.
    Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU (2019) Bladder preservation with twice-a-day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG/RTOG 0712-A randomized phase II trial. J Clin Oncol 37(1):44–51Google Scholar
  147. 147.
    James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA, Investigators BC (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366(16):1477–1488.  https://doi.org/10.1056/NEJMoa1106106 Google Scholar
  148. 148.
    Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD, The National Cancer Institute of Canada Clinical Trials Group (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14(11):2901–2907.  https://doi.org/10.1200/jco.1996.14.11.2901 Google Scholar
  149. 149.
    Feuerstein MA, Goenka A (2015) Quality of life outcomes for bladder cancer patients undergoing bladder preservation with radiotherapy. Curr Urol Rep 16(11):75.  https://doi.org/10.1007/s11934-015-0547-1 Google Scholar
  150. 150.
    Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27(25):4055–4061.  https://doi.org/10.1200/JCO.2008.19.5776 Google Scholar
  151. 151.
    Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, Talcott JA, Shipley WU (2003) Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 170(5):1772–1776.  https://doi.org/10.1097/01.ju.0000093721.23249.c3 Google Scholar
  152. 152.
    Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA (2016) Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 96(5):1028–1036.  https://doi.org/10.1016/j.ijrobp.2016.08.023 Google Scholar
  153. 153.
    Royce TJ, Feldman A, Mossanen M, Yang J, Shipley WA, Pandharipande P, Efstathiou JA (2018) Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer. Clin Genitourin Cancer.  https://doi.org/10.1016/j.clgc.2018.09.023
  154. 154.
    Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, Kelly JD, Kirkbank T, McLaren DB, Mead G, Moynihan C, Persad R, Scrase C, Lewis R, Hall E (2017) Clinical and patient-reported outcomes of SPARE—a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int 120(5):639–650.  https://doi.org/10.1111/bju.13900 Google Scholar
  155. 155.
    Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumours. Eur Urol 70(1):106–119.  https://doi.org/10.1016/j.eururo.2016.02.028 Google Scholar
  156. 156.
    Alanee S, Alvarado-Cabrero I, Murugan P, Kumar R, Nepple KG, Paner GP, Patel MI, Raspollini MR, Lopez-Beltran A, Konety BR (2018) Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World J Urol.  https://doi.org/10.1007/s00345-018-2421-5 Google Scholar
  157. 157.
    Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP (2006) Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176(4 Pt 1):1354–1361.  https://doi.org/10.1016/j.juro.2006.06.025 (discussion 1361-1352) Google Scholar
  158. 158.
    Bayoumi Y, Heikal T, Darweish H (2014) Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients. Cancer Manag Res 6:459–465.  https://doi.org/10.2147/CMAR.S69055 Google Scholar
  159. 159.
    Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E, Ribal MJ (2012) Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol 62(2):290–302.  https://doi.org/10.1016/j.eururo.2012.05.008 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Jeffrey J. Leow
    • 1
  • Jens Bedke
    • 2
  • Karim Chamie
    • 3
  • Justin W. Collins
    • 4
    • 5
  • Siamak Daneshmand
    • 6
  • Petros Grivas
    • 7
  • Axel Heidenreich
    • 8
  • Edward M. Messing
    • 9
  • Trevor J. Royce
    • 10
  • Alexander I. Sankin
    • 11
  • Mark P. Schoenberg
    • 11
  • William U. Shipley
    • 12
  • Arnauld Villers
    • 13
  • Jason A. Efstathiou
    • 12
    Email author
  • Joaquim Bellmunt
    • 14
    Email author
  • Arnulf Stenzl
    • 2
    Email author
  1. 1.Department of UrologyTan Tock Seng HospitalSingaporeSingapore
  2. 2.Department of UrologyUniversity of TübingenTübingenGermany
  3. 3.Department of Urology and Institute of Urologic OncologyDavid Geffen School of Medicine at University of CaliforniaLos AngelesUSA
  4. 4.Department of Molecular Medicine and Surgery (MMK)Karolinska InstitutetSolnaSweden
  5. 5.Orsi AcademyMelleBelgium
  6. 6.USC Institute of Urology, University of Southern CaliforniaLos AngelesUSA
  7. 7.Division of Oncology, Department of MedicineUniversity of WashingtonSeattleUSA
  8. 8.Department of UrologyUniversity Hospital of CologneCologneGermany
  9. 9.Department of UrologyUniversity of Rochester Medical Center, University of Rochester School of Medicine and DentistryRochesterUSA
  10. 10.Department of Radiation OncologyUniversity of North Carolina at Chapel Hill School of MedicineChapel HillUSA
  11. 11.Department of UrologyMontefiore Medical Center, Albert Einstein College of MedicineBronxUSA
  12. 12.Genitourinary Division, Department of Radiation OncologyMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  13. 13.Department of UrologyUniversity of Lille Nord de FranceLilleFrance
  14. 14.PSMAR-IMIM Hospital del Mar Medical Research InstituteBarcelonaSpain

Personalised recommendations